project id: TCGA-CESC; case submitter id: TCGA-EK-A3GK; source center: 23; state: released; a260 a280 ratio: 1.86; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 2.2; rna integrity number: 10.0; age at index: 33; days to birth: -12207; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1976; age at diagnosis: 12207; ajcc pathologic m: MX; ajcc pathologic n: N0; ajcc pathologic t: T1b1; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 15.0; figo stage: Stage IB1; icd 10 code: C53.9; last known disease status: not reported; morphology: 8384/3; primary diagnosis: Adenocarcinoma, endocervical type; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Cervix uteri; synchronous malignancy: No; tissue or organ of origin: Cervix uteri; tumor grade: Not Reported; year of diagnosis: 2009; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 744; initial weight: 90.0; oct embedded: false; preservation method: Unknown; sample id: f9371b06-c6e5-4363-bdaa-bd85f95a01c4; sample submitter id: TCGA-EK-A3GK-01A; portion id: 0103f635-0471-48ef-a4a2-964d4789a216; portion submitter id: TCGA-EK-A3GK-01A-11; slide id: 1dbdc040-f79f-4892-8a00-6efd60f5f4c2; slide submitter id: TCGA-EK-A3GK-01A-01-TSA; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 0.0; percent necrosis: 2.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 2.0; percent tumor cells: 96.0; percent tumor nuclei: 96.0; section location: TOP;